Picard Medical, Inc. (PMI)
AMEX AMEX Primary Summary
Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript
Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript
Picard Medical, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 0.3 | $16 | $1.44 | -$14.56 | -91% |
 Bobby Adusumilli SJS Investment Consulting Inc. | - | $3.12 | $0.01 | -$3.11 | -99.68% |
 Drew Phillips Fortitude Family Office LLC | 1.86 | $804.8 | $8.17 | -$796.63 | -98.98% |
 Kevin Kroskey True Wealth Design LLC | 0.01 | $30 | $0.05 | -$29.95 | -99.83% |
 Christopher C. Powers Farther Finance Advisors, LLC | 0.33 | $153.65 | $72.6 | -$81.05 | -52.75% |
Picard Medical, Inc. (PMI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Picard Medical, Inc. ever had a stock split?
Picard Medical, Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Richard Fang CEO | AMEX Exchange | 71953R108 CUSIP |
| US Country | 75 Employees | - Last Dividend | 3 Aug 2026 Last Split | - IPO Date |
Overview
Picard Medical, Inc. is a forward-thinking medical device company that focuses on the design, manufacture, and marketing of innovative healthcare solutions. Established in 2021, the company operates from its headquarters in Tucson, Arizona, and has a global footprint, serving markets in the USA and Europe, as well as other international regions. The company stands as a subsidiary of Hunniwell Picard I, LLC, leveraging its resources and expertise to advance the development of life-saving medical technologies, particularly in the field of artificial hearts.
Products and Services
- SynCardia TAH
The SynCardia Total Artificial Heart (TAH) is a groundbreaking medical device designed for patients diagnosed with advanced heart failure. It serves as a bridge to heart transplantation or, in certain cases, as a long-term solution to replace the failing human heart. This innovative product mimics the essential functions of a normal heart, allowing patients to regain their quality of life while awaiting a suitable donor organ. The TAH is recognized for its exceptional performance and is a testament to Picard Medical's commitment to improving patient outcomes in the field of cardiology.
